Merck’s Keytruda, for example ... AbbVie expects Skyrizi and Rinvoq to hit a combined $27 billion in sales by 2027. Amgen’s blockbuster drug Neulasta—used to stimulate neutrophil growth primarily in ...

The drugmaker Merck announced it has opened a $1 billion vaccine manufacturing facility in north Durham, a 225,000-square-foot addition to the company’s existing campus off Old Oxford Road.

Neulasta (pegfilgrastim) is a prescription drug used to help prevent infection from certain types of chemotherapy and to treat radiation sickness. Neulasta can interact with certain other ...

Merck’s MRK fourth-quarter revenue grew 7% to $15.6 billion (including Keytruda growth of 21% to $7.8 billion), in line with overall 7% growth for the year. Shares fell more than 10% as Merck ...

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, has secured Merck global rights to LaNova Medicines’ PD-1xVEGF ...

Agreement expands Meitheal’s portfolio to eight biosimilars across diabetes, oncology, fertility, and autoimmune indications Portfolio growth underscores Meitheal’s commitment to sustainable patient ...

Merck will face an important patent cliff by the end of the decade. The company has a plan to move beyond it. Competition from a new therapy shouldn't derail Merck's prospects. Even when we zoom ...

Before you start treatment with Neulasta, tell your doctor and pharmacist which prescription, over-the-counter, and other medications you take. By sharing this information with them, you may help ...

Neulasta (pegfilgrastim) is a brand-name drug that’s prescribed to treat radiation sickness and prevent certain complications of chemotherapy. Neulasta comes as an injectable solution. The ...